Key threats to progress.
The year 2024 was marked by significant biological, systemic and financial challenges. Antimalarial drug resistance and P. falciparum histidine-rich protein 2 and 3 (pfhrp2/3) gene deletions continued to compromise the effectiveness of case management, while widespread insecticide resistance reduced the impact of vector control tools. Anopheles stephensi further expanded its range and is now reported in nine African countries, heightening urban malaria risks. Beyond biological threats, climate change, conflict and humanitarian crises continue to drive malaria resurgence and disrupt essential services. ■ Globally in 2024, total investments in malaria control reached an estimated US$ 3.9 billion. Based on the 2025 GTS target of $9.3B, this corresponds to a projected shortfall of about $5.4B, with only 42% of required funding attained. ■ Between 2010 and 2024, about 67% of malaria funding came from international sources, while endemic countries supplied 33%. In 2024, about 56%...